Don Husereau1, Chris Henshall2, Laura Sampietro-Colom3, Sarah Thomas4. 1. Institute of Health Economics,School of Epidemiology,Public Health and Preventive Medicine,University of Ottawa,University for Health Sciences,Medical Informatics and Technologydhusereau@ihe.ca. 2. Health Economics Research Group,Brunel University London. 3. Hospital Clinic. 4. Wessex Institute Enterprise and Partnerships,University of Southampton.
Abstract
OBJECTIVES: Health technology assessment (HTA) has to innovate to best support changing health system environments and to help provide access to valuable innovation under fiscal constraint. METHODS: Issues associated with changing HTA paradigms were identified through scoping and explored through deliberation at a meeting of industry and HTA leaders. RESULTS: Five broad areas of change (engagement, scientific dialogue, research prioritization, adaptive approaches, and real world data) were identified. The meeting focused on two themes derived from these: re-thinking scientific dialogue and multi-stakeholder engagement, and re-thinking value, affordability, and access. Earlier and ongoing engagement to steer the innovation process and help achieve appropriate use across the technology lifecycle was perceived as important but would be resource intensive and would require priority setting. Patients need to be involved throughout, and particularly at the early stages. Further discussion is needed on the type of body best suited to convening the dialogue required. There was agreement that HTA must continue to assess value, but views differed on the role that HTA should play in assessing affordability and on appropriate responses to challenges around affordability. Enhanced horizon scanning could play an important role in preparing for significant future investments. CONCLUSIONS: Early and ongoing multi-stakeholder engagement and revisiting approaches to valuing innovation are required. Questions remain as to the most appropriate role for HTA bodies. Changing HTA paradigms extend HTA's traditional remit of being responsive to decision-makers demands to being more proactive and considering whole system value.
OBJECTIVES: Health technology assessment (HTA) has to innovate to best support changing health system environments and to help provide access to valuable innovation under fiscal constraint. METHODS: Issues associated with changing HTA paradigms were identified through scoping and explored through deliberation at a meeting of industry and HTA leaders. RESULTS: Five broad areas of change (engagement, scientific dialogue, research prioritization, adaptive approaches, and real world data) were identified. The meeting focused on two themes derived from these: re-thinking scientific dialogue and multi-stakeholder engagement, and re-thinking value, affordability, and access. Earlier and ongoing engagement to steer the innovation process and help achieve appropriate use across the technology lifecycle was perceived as important but would be resource intensive and would require priority setting. Patients need to be involved throughout, and particularly at the early stages. Further discussion is needed on the type of body best suited to convening the dialogue required. There was agreement that HTA must continue to assess value, but views differed on the role that HTA should play in assessing affordability and on appropriate responses to challenges around affordability. Enhanced horizon scanning could play an important role in preparing for significant future investments. CONCLUSIONS: Early and ongoing multi-stakeholder engagement and revisiting approaches to valuing innovation are required. Questions remain as to the most appropriate role for HTA bodies. Changing HTA paradigms extend HTA's traditional remit of being responsive to decision-makers demands to being more proactive and considering whole system value.
Authors: Daniel M Walker; Jennifer L Hefner; Cynthia J Sieck; Timothy R Huerta; Ann Scheck McAlearney Journal: J Med Syst Date: 2018-07-16 Impact factor: 4.460
Authors: Maria Dimitrova; Ivett Jakab; Zornitsa Mitkova; Maria Kamusheva; Konstantin Tachkov; Bertalan Nemeth; Antal Zemplenyi; Dalia Dawoud; Diana M J Delnoij; François Houýez; Zoltan Kalo Journal: Front Public Health Date: 2022-07-28
Authors: Melanie A Lindenberg; Valesca P Retèl; Joost H van den Berg; Marnix H Geukes Foppen; John B Haanen; Wim H van Harten Journal: J Immunother Date: 2018 Nov/Dec Impact factor: 4.456